SEC Form 4

~~-------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION -----------------------------~~ FORM 4 ~~WASHINGTON,~~[ ~~D.C.~~] ~~20549~~Check ~~OMB~~this ~~APPROVAL~~box ~~--------~~if ~~-----------------------------~~no /longersubject /to ~~CHECK~~Section ~~THIS~~16. ~~BOX~~Form IF4 NOor ~~STATEMENT~~Form5 OFobligations ~~CHANGES~~may INcontinue.See ~~BENEFICIAL~~Instruction ~~OWNERSHIP~~1(b). ~~OMB~~UNITED ~~NUMBER:~~STATES ~~3235-0287~~SECURITIES ~~LONGER~~AND ~~SUBJECT~~EXCHANGE TOCOMMISSION ~~EXPIRES:~~Washington, ~~JANUARY~~D.C. ~~31,~~20549 ~~2005~~STATEMENT ~~SECTION~~OF ~~16.~~CHANGES ~~FORM~~IN 4BENEFICIAL OROWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, ~~ESTIMATED AVERAGE BURDEN FORM 5 OBLIGATIONS MAY~~ Section 17(a) of the Public Utility Holding Company Act of 1935 or ~~HOURS PER RESPONSE .... 0.5 CONTINUE. SEE~~ Section 30(h) of the Investment Company Act of 1940 ~~-----------------------------~~OMB ~~INSTRUCTION~~APPROVAL ~~1(b).~~OMB (Print or Type Responses) ------------------------------------------------------------------------------------------------------------------------------------ 1. Name and Address of Reporting Person* 2. Issuer Name AND Ticker or Trading Symbol 6. Relationship of Reporting Person(s) to Issuer (Check all applicable) Genzyme Corporation X Director 10% Owner Carpenter, Robert J. GENZ, GZBX and GZMO ---- ---- --------------------------------------------------------------------------------------------- Officer (give Other (Last) (First) (Middle) 3. I.R.S. Identification 4. Statement for ---- title ---- (specify Number: ~~of Reporting Month/Day/Year below) below) c/o Genzyme Corporation Person, if an entity~~ 3235-~~----------------~~0287 ~~------------------~~Expires: ~~One~~January ~~Kendall Square (voluntary) 10/18/02 -------------------------------------------- --------------------- 7. Individual or Joint/Group Filing (Street) 5. If Amendment~~31, ~~(Check~~2005Estimated ~~Applicable~~average ~~Line)~~burdenhours ~~Date~~per of Original _X_Form filed by One Reporting Person (Month/Day/Year) ___Form filed by More than One Cambridge, MA 02139 Reporting Person ------------------------------------------------------------------------------------------------------------------------------------ (City) (State) (Zip) TABLE I - NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED ------------------------------------------------------------------------------------------------------------------------------------ 1response. ~~Title of 2~~. ~~Trans- 2A~~. ~~Deemed 3~~. ~~Trans- 4~~. ~~Securities Acquired (A) 5~~0. ~~Amount of 6. Owner- 7. Nature Security action Execution action or Disposed of (D) Securities ship of In- (Instr. 3) Date Date, Code (Instr. 3, 4 and~~ 5) Beneficially Form: direct if any (Instr. 8) Owned Follow- Direct Bene- (Month/ (Month/ ing Reported (D) or ficial Day/ Day/ ------------------------------------------ Transaction(s) Indirect Owner- Year) Year) (A) or (Instr. 3 (I) ship Code V Amount (D) Price and 4) (Instr. 4) (Instr. 4) ------------------------------------------------------------------------------------------------------------------------------------ Genzyme General Division common stock (GENZ) 10/15/02 W V 700 A 152,088 D ------------------------------------------------------------------------------------------------------------------------------------ Genzyme General Division common stock (GENZ) 10/18/02 J(1) 5,700 D $69.22 146,388 D ------------------------------------------------------------------------------------------------------------------------------------ Genzyme General Division common stock (GENZ) 696 I By spouse ------------------------------------------------------------------------------------------------------------------------------------ Genzyme General Division common By 401(k) stock (GENZ) 1,758 I plan ------------------------------------------------------------------------------------------------------------------------------------ Genzyme Biosurgery Division common stock (GZBX) 10/15/02 W V 81 A 7,128 D ------------------------------------------------------------------------------------------------------------------------------------ Genzyme Biosurgery Division common stock (GZBX) 52 I By spouse ------------------------------------------------------------------------------------------------------------------------------------ Genzyme Molecular Oncology Division common stock (GZMO) 10/15/02 W V 90 A 1,113 D ------------------------------------------------------------------------------------------------------------------------------------ Genzyme Molecular Oncology Division common stock (GZMO) 41 I By spouse ------------------------------------------------------------------------------------------------------------------------------------ /s/ Susan P. Cogswell, Attorney-in-Fact --------------------------------------- ----------- **Signature of Reporting Person Date

FORM 4 (CONTINUED) TABLE II - DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED (E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES) ----------------------------------------------------------------------------------------------------------------------------------- 1. ~~Title~~Name ofand ~~Derivative~~Address ~~Security 2. Conver- 3. Trans- 3A. Deemed 4. Transac- 5. Number~~ of ~~Deriv-~~Reporting 6.Person* ~~Date~~Carpenter, ~~Exer-~~Robert (~~Instr. 3~~Last) ~~sion or action Execution tion Code ative Securities Ac- cisable and Ex- Exercise Date Date,~~ (~~Instr. 8~~First) ~~quired~~ (AMiddle) or16931 ~~Dis-~~Millikan ~~piration~~Avenue ~~Date Price of~~ (~~Month/ if any posed of (D~~Street) ~~(Month/Day/ Deriv- Day/ (Month/ (Instr. 3~~Irvine, 4,CA ~~and~~92606 ~~5) Year) ative Year) Day/ Security Year) -------------------------------------- ---------------- Date Expira- Exer- tion Code V~~ (ACity) (DState) ~~cisable Date ----------------------------------------------------------------------------------------------------------------------------------- PEACS Transaction~~ (~~Obligation to sell~~Zip) ~~(1) $70~~2.~~0005~~ ~~10/18/02~~Issuer ~~10/18/02~~Name J(1) 1 10/18/02 10/18/02 ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- 7. Title and ~~Amount~~Ticker ofor 8.Trading ~~Price~~Symbol ofCardiac 9.Science, ~~Number of 10~~Inc.DFIB ~~Ownership 11. Nature of Underlying Securities Derivative Derivative Form of Indirect (Instr.~~ 3 ~~and 4) Security Securities Derivative Beneficial (Instr~~. ~~5) Beneficially Securities: Ownership Owned Direct (D) or (Instr. 4) Following Indirect (~~I~~) Reported (Instr~~. ~~4) Transaction(s) ----------------------- (Instr~~R.S. 4)Identification ~~Title Amount or~~ Number of ~~Shares~~Reporting ~~----------------------------------------------------------------------------------------------- Genzyme General 5~~Person,~~700~~ 0if ~~common~~an ~~stock~~entity ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- Explanation of Responses: (1voluntary) ~~Premium Equity Amortizing Contingent Sales (PEACS) Transaction~~4. OnStatement ~~October~~for ~~18,~~Month/Day/Year ~~2002~~10/24/02 Mr5. ~~Carpenter~~If ~~terminated the PEACS Transaction prior to its maturity~~Amendment, ~~resulting~~Date ~~in his obligation to deliver 5,700 shares~~ of ~~Genzyme~~Original ~~General common stock at a per share purchase price of $69.22.~~ (Month/sDay/Year) ~~Susan P~~6. ~~Cogswell,~~Relationship ~~Attorney-in-Fact --------------------------------------- ----------- **Signature~~ of Reporting Person ~~Date ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff~~(as). ~~Note:~~to ~~File~~Issuer ~~three~~(Check ~~copies~~all ofapplicable) ~~this~~X ~~Form,~~Director ~~one~~10% ofOwner ~~which~~Officer ~~must~~(give betitle ~~manually~~below) ~~signed.~~Other If(specify ~~space~~below) isDescription ~~insufficient, SEE Instruction 6 for procedure~~7. ~~POTENTIAL~~Individual ~~PERSONS~~or ~~WHO~~Joint/Group ~~ARE~~Filing TO(Check ~~RESPOND~~Applicable TOLine) ~~THE~~X ~~COLLECTION~~Form OFfiled ~~INFORMATION~~by ~~CONTAINED~~One INReporting ~~THIS~~Person ~~FORM~~Form ~~ARE~~filed ~~NOT~~by ~~REQUIRED~~More TOthan ~~RESPOND~~One ~~UNLESS~~Reporting ~~THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.~~Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security
(Instr. 3)

2.Transaction
Date
(Month/Day/Year)

2A. Deemed Execution Date, if any
(Month/Day/Year)

3. Transaction
Code
(Instr. 8)

4. Securities Acquired (A) or Disposed Of (D)
(Instr. 3, 4, and 5)

5. Amount of
    Securities
    Beneficially
    Owned Following
    Reported Transaction(s)

    (Instr. 3 and 4)

6. Owner-
    ship
    Form:
    Direct (D)
    or
    Indirect (I)

    (Instr. 4)

7. Nature of
     Indirect
     Beneficial
     Ownership

    (Instr. 4)

Code

Amount

A/D

Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conver-
    sion or
    Exercise
    Price of
    Deri-
    vative
    Security

3. Transaction Date

(Month/
Day/
Year)

3A. Deemed Execution Date, if any

(Month/
Day/
Year)

4. Transaction Code
(Instr.8)

5. Number of Derivative
    Securities Acquired (A)
    or Disposed Of (D)

    (Instr. 3, 4 and 5)

6. Date Exercisable(DE) and
Expiration Date(ED)
(Month/Day/Year)

7. Title and Amount of
Underlying Securities
(Instr. 3 and 4)

8. Price
    of
    Derivative
    Security
    (Instr.5)

9. Number of
    Derivative
    Securities
    Beneficially
    Owned
    Following
    Reported
    Transaction(s)
    (Instr.4)

10. Owner-
ship
Form of
Deriv-
ative
Securities:
Direct (D)
or
Indirect (I)

(Instr.4)

11. Nature of
      Indirect
      Beneficial
      Ownership
      (Instr.4)

Code

Title

Amount or Number of Shares

Non Qualified Stock Option (RIGHT TO BUY)

$1.75

10/24/02

25,000

(1)

10/24/12

Common Stock

25,000

80000

Explanation of Responses:

(1) The option vests in 48 equal installements beginning 11/24/02.

By:
/s/ Robert Carpenter 10/29/02
** Signature of Reporting Person Date

SEC 1474 (8-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.

Filing Compare · CARPENTER ROBERT J